The FDA grants orphan drug designation to TRX-E-002-1, an investigational small-molecule benzopyran, for the treatment of acute myeloid leukemia (AML).
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
The phase 3 GIMEMA ALL2820 trial found improved event-free survival and molecular responses with frontline ponatinib plus blinatumomab vs imatinib and chemotherapy.